Market opportunity for new prostate cancer diagnostic biomarkers

When we do a market assessment or commercial landscape for a therapeutic area or new product, one of the things we look at is emerging new treatments or diagnostics. It’s important to understand the impact these may have on the market opportunity.

Recent research published in the AACR journal Clinical Cancer Research suggests that Engrailed-2 (EN2) may have potential as a biomarker for the diagnosis and treatment of prostate cancer (PC).

In a post on Biotech Strategy Blog, Pieter Droppert discusses the clinical data comparing EN2 to measurement of serum prostate specific antigen (PSA).


, , , , , , , , , , , , , , , , , ,

error: Content is protected !!